about
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growthCDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancerQuantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumorsIntegrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma.Performance of mitochondrial DNA mutations detecting early stage cancer.Association between lifestyle factors and CpG island methylation in a cancer-free population.Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCRAn epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urineForced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells.OGDHL is a modifier of AKT-dependent signaling and NF-κB function.Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection.Pharmacologic unmasking of epigenetically silenced genes in breast cancerAssociation of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.Genome-wide promoter analysis uncovers portions of the cancer methylome.Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.Epigenomics and ovarian carcinoma.Living kidney donors ages 70 and older: recipient and donor outcomes.Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation.Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury during transplantation.Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNACorrelation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.Epigenetic silencing of S100A2 in bladder and head and neck cancersEvaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer.N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer.Patient-derived xenografts as tools in pharmaceutical development.Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitorsMitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now?AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer.Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer.
P50
Q24310660-FC064BF3-E39F-41F9-A383-CA6F005A49D1Q24318511-830EE2EF-0BD2-45A9-B3D9-33547B5D2D38Q28751911-82D574E6-248F-41E7-85BF-6C0005A70824Q30426166-BD856425-F777-477E-BBD8-4E1DF2FFD35BQ33373844-DCA40B22-F8E2-4E08-940D-2DE10B78439EQ33886934-EF2A023A-31FE-4792-97A1-9B3B215B9A06Q33917646-D4B3D638-B9C6-41A6-9F09-8E9F08CBCF78Q33974374-36F0CA1A-4442-4817-BA00-A54BC748E6A7Q34221765-719FB0DA-2209-44BE-BD96-943B52BB6E85Q34334234-FC72908E-8A2B-4761-A60E-B0E8354E68C8Q34477450-94157465-1959-426F-B1FC-99F1BBA3518AQ34634621-7D88C358-4273-486B-B665-9C39A0D0DD12Q34858991-D0C0DAE4-528C-49C6-90DC-06BFCD0EFED7Q35004607-A132D08F-19DC-4174-AABF-337538CC08F8Q35008027-25C321E0-5205-49D9-9158-78E4DA6FF415Q35096116-E164965B-1F7E-4592-866A-282D2F26EC49Q35164353-B3A368E1-7F3D-44EE-822E-C14ACCC0D9C3Q35322421-FF0737C7-9DD9-4637-B62B-9793C29D97BFQ35636575-9302ACA1-C17E-4F19-842D-0DA7D3037478Q35664558-854E539B-28F8-48D3-9026-F9C550DE5CABQ35866471-35FAA729-D283-4A72-8342-0C24F1F4B66CQ36002695-38EB4F25-C5E3-4DA9-A210-64D27218D39AQ36102469-8AAC248D-256C-4B95-A27F-ED3D86AA6677Q36128449-0F021231-A26C-449E-8070-2EE29279C3A2Q36149220-BE4172FC-C986-4DF8-84F3-8A26BEEBE0FAQ36953349-4EF3D78D-1DF3-4010-AE8F-31070AE28CD3Q37012561-AE80C867-A4FB-4318-8F71-9ABC74EFF184Q37173021-3311FAF9-AD26-45CE-8692-5946908CC5CBQ37424550-E8D264EF-8EE1-4A76-A694-05E4975F7A9BQ38424946-102C2A18-3B3B-44BC-90E9-DA22397892D4Q38502777-54B22034-D25B-4AC7-AE4F-A7D9C0006871Q38503698-D7764CCA-A8E1-4D8B-9749-56B0C3F08648Q38510606-C249E143-BBED-4156-BEE6-5A7B38051FA7Q38732336-976FD6C3-069F-4F7E-BEE7-C8A57E44CD0BQ38739860-1BD6386B-FEDE-4705-BA49-75DB5A36C063Q38994746-4D3254A0-56F1-4999-99CD-5BB2E3B3ED3DQ39361908-C049253A-F1B7-4214-8816-DCAA8E75CC31Q39441173-74D2FAE8-616F-4324-A4AA-C2A9DBEDB9ADQ40224379-99FC4651-EC83-40D2-84DE-9152A2BE78D7Q40243365-C2D5042D-C0DC-4B04-AB6A-E12C88319ACA
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-6701-9978
@en
name
Mohammad Obaidul Hoque
@ast
Mohammad Obaidul Hoque
@en
Mohammad Obaidul Hoque
@es
Mohammad Obaidul Hoque
@nl
type
label
Mohammad Obaidul Hoque
@ast
Mohammad Obaidul Hoque
@en
Mohammad Obaidul Hoque
@es
Mohammad Obaidul Hoque
@nl
prefLabel
Mohammad Obaidul Hoque
@ast
Mohammad Obaidul Hoque
@en
Mohammad Obaidul Hoque
@es
Mohammad Obaidul Hoque
@nl
P106
P1153
7102990428
P31
P496
0000-0001-6701-9978